Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

535

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Type 2 Diabetes
Interventions
DRUG

Chiglitazar

Take orally

DRUG

Placebo

Take orally

Trial Locations (26)

100000

Peking University Shougang Hospital, Beijing

100028

China Meitan General Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100101

The 306th Hospital of PLA, Beijing

130041

The Second Hospital of Jilin University, Changchun

150081

The First Affiliated Hospital of Ha'erbin Medical University, Harbin

200032

Zhongshan Hospital Fudan University, Shanghai

200092

Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

200433

The Central Hospital of Yangpu District of Shanghai, Shanghai

210029

The people's Hospital of Jiangsu Province, Nanjing

221000

The Affiliated Hospital of Xuzhou Medical College, Xuzhou

266071

The Affiliated Hospital of Qingdao Medical University, Qingdao

300052

The General Hospital of Tianjin Medical University, Tianjin

400016

The First Affiliated Hospital of Chongqing Medical University, Chongqing

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

404000

Chongqing Three Gorges Central Hospital, Chongqing

410001

The Second Xiangya Hospital of Central South University, Changsha

423000

Chenzhou First People's Hospital, Chenzhou

430071

Zhongnan Hospital of Wuhan University, Wuhan

610041

Huaxi Hopsital of Sichuan University, Chengdu

710032

The First Affiliated Hospital of The 4th Military Medical University, Xi’an

061110

Cangzhou's Central Hospital, Cangzhou

053000

Harrison International Peace Hospital, Hengshui

050051

The Third Hospital of Hebei Medical University, Shijiazhuang

063000

Tangshan Gongren Hospital, Tangshan

014010

Baogang Hospital of Inner Mongilia, Baotou

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY